A joint effort between Leiden University’s Professor Ubbink’s lab and ZoBio’s Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane proteins. Supported by a Dutch Research Council (NWO) AES grant, the project utilized protein-lipid nanodiscs to study how lipid composition affects small molecule interactions with the membrane enzyme CYP3A4.
Findings revealed that lipid types significantly influence off-target binding, underscoring the importance of lipid selection in drug screening. This research, published in Chemical Biology and Drug Design, offers valuable insights for developing therapeutics targeting complex membrane proteins
Read more here
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By...
The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer, more respectful workplaces.
Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme. The funding will support the...